Skip to main content

Table 1 Details of the included randomized controlled trials

From: Inhaled nitric oxide therapy and risk of renal dysfunction: a systematic review and meta-analysis of randomized trials

Study (year)

Country

Study population

Protocol of iNO therapy

Mean iNO dosage

Age, years

Definition of acute kidney injury (AKI)

Number of AKI/number of cases

iNO

Control

Dellinger (1998) [12]

USA

ARDS

1.25, 5.0, 20.0, 40.0, or 80.0 ppm iNO for 28 days or till FiO2 < 0.5

21 ppm

48

Creatinine >2 mg/dL

20/120

7/57

Creatinine ≥3.5 mg/dL

13/120

5/57

Lundin (1999) [20]

11 European countries

ARDS

1 to 40 ppm iNO at the lowest effective dose for up to 30 days or until an end point was reached

9 ppm

57

Creatinine >3.4 mg/dL or RRT

28/80

12/74

Incident RRT

23/84

10/79

Kinsella (1999) [22]

USA

Neonate hypoxemic respiratory failure

5 ppm for 7 days

5 ppm

27 weeks

Renal failure

2/48

2/32

Payen (1999) [21]

Europe

ARDS

10 ppm till PF >250, median 5 days

10 ppm

Not reported

RRT

33/98

26/105

Taylor (2004) [23]

USA

ARDS

5 ppm until 28 days, discontinuation of assisted breathing, or death

5 ppm

50

Creatinine ≥3 mg/dL

12/192

8/193

Creatinine ≥3.5 mg/dL

10/192

6/193

Perrin (2006) [24]

France

Lung transplantation

20 ppm for 12 h

20 ppm

35

RRT

1/15

1/15

Potapov (2011) [26]

USA and Germany

Cardiac surgery

40 ppm for 48 h

40 ppm

56

RRT

10/73

8/77

Fernandes (2011) [25]

Brazil

Cardiac surgery

10 ppm for 48 h

10 ppm

46

Urine output <0.3 ml/kg/h

0/14

1/15

Lang (2014) [28]

USA

Liver transplantation

80 ppm during the operative phase

80 ppm

56

Renal dysfunction

3/40

7/40

Trzeciak (2014) [27]

USA

Sepsis

40 ppm for 6 h

40 ppm

59

RRT

2/26

1/23

  1. AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; iNO, inhaled nitric oxide; FiO2: inspired oxygen fraction; PF: PaO2/FiO2 ratio; RRT: renal replacement therapy.